RANBAXY
Delhi court reprimands Nora Fatehi in Rs 200 crore extortion case as fresh summons issued: 'Conduct is not up to the mark'
Nora Fatehi has been ordered to appear in court on November 2 as a witness in an extortion case. This case involves alleged conman Sukesh Chandrasekhar, who is accused of extorting Rs 200 crore. The court issued this order on October 16, highlighting Fatehi's significance as a witness.
SC draws the line on Fortis audit, says no ‘fishing and roving’ probe into banks
The Supreme Court clarified the forensic audit's focus is on Fortis Healthcare Holdings Private Limited and the Singh Brothers. This audit is not a broad inquiry into the dealings of other banks. The court highlighted the audit relates specifically to transactions between FHHPL, FHL, and banks involved. The clarification came in response to a prior ruling by the Delhi High Court.
SC clears forensic audit of Fortis-IHH deal involving erstwhile Religare promoters Singh brothers
The Supreme Court has cleared the way for a Delhi High Court-appointed forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’s IHH Healthcare and entities linked to former promoters Malvinder and Shivinder Singh. The audit will trace assets linked to the brothers and examine the dilution of their Fortis shareholding.
Supreme Court backs Delhi HC orders in Daiichi-Fortis dispute, clears way for forensic audit
The Supreme Court has declined to interfere with Delhi High Court orders in the long-running Daiichi Sankyo-Fortis dispute, allowing a forensic audit to proceed as part of efforts to trace assets linked to enforcement of a 2016 arbitral award against former Fortis promoters. The apex court did not examine the merits.
Yes Bank moves SC against forensic audit in Fortis share sale issue
Yes Bank has approached the Supreme Court challenging a recent Delhi High Court directive. The court ordered a forensic audit into the sale of Fortis Healthcare shares. Yes Bank argues it was not a party to the original arbitration proceedings. However, the bank does not oppose auditing Fortis and its former promoters. It will provide relevant transaction information within legal limits.
Delhi HC orders forensic audit of Fortis, Singh brothers' Rs 4,666-crore trail
The Delhi High Court ordered a forensic audit of Fortis Healthcare transactions. This audit will examine dealings with IHH Healthcare Berhad and RHT Health Trust. It will also probe transactions involving the Singh brothers and Religare Group companies. The court seeks to trace the movement of shares and funds. This comprehensive audit must be completed within six months.
Daiichi-Ranbaxy case: Delhi HC orders forensic audit into transactions of Fortis, Singh brothers
The Delhi High Court has appointed a forensic auditor to examine transactions. This audit aims to trace the dissipation of Fortis Healthcare shares. The former promoters, Malvinder and Shivinder Singh, are involved in these dealings. A Rs 3,500 crore arbitral award favors Japanese firm Daiichi Sankyo. The court seeks to reconstruct events and identify involved parties.
Delhi HC orders forensic audit of Fortis, IHH and RHT transactions in $4.6-billion Daiichi-Singh case
The Delhi High Court on Monday ordered the appointment of a forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’s IHH Healthcare and Singapore’s RHT Health Trust, in a case linked to a $4.6-billion arbitration award won by Daiichi Sankyo against Malvinder and Shivinder Singh.
Sun Pharma’s acquisition: Is this the end of road for the 50-plus-year brand Ranbaxy?
Former Ranbaxy officials lament that rival Sun Pharma’s acquisition of the co would mark the death of the brand, which has been ailing for too long.
Sun Pharma-Ranbaxy deal: Daichi Sankyo failed to harness the complexities of a strong generic business, says Malvinder Singh
The Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.
Sun Pharma to buy Ranbaxy in $3.2 bn deal: Highlights
Sun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market over quality issues.
Ranbaxy Q3 top-line seen up 33% at Rs 2698 crore
Ranbaxy is expected to report a 33 per cent jump in its net sales for the quarter ended September 30 to Rs 2698 crore.
Ranbaxy launches generic version of Evoxac in US market
Ranbaxy has launched generic cevimeline hydrochloride capsules, used in treating Sjogren's syndrome, in the US market.
Ranbaxy opens new manufacturing facility in Morocco; eyes $1 bn drug market
Ranbaxy has opened a new production facility in Morocco, a move which would help the drug maker access the African nation's $1 billion pharma market.
Ranbaxy laboratories may hand over Latin American operations to Daiichi Sankyo
Ranbaxy may hand over its L American mkting operations to Daiichi Sankyo, a move could be a precursor to the Indian drugmaker's exit from some countries.
Ranbaxy to sell Daiichi Sankyo product in Malaysia
Drug firm Ranbaxy Laboratories and Japan's Daiichi Sankyo today said Ranbaxy will market its parent company's products in Malaysia.
Ranbaxy: Less aggressive, more Japanese and more healthy after 3 years under Japan's Daiichi
Under Daiichi, Ranbaxy is emerging as a less aggressive, less confrontational, less communicative and more Japanese and more healthy.
Daiichi to use Ranbaxy network to sell products in Singapore
Ranbaxy and Daiichi Sankyo had signed a three-year plan to exploit synergies in operations to enhance their generic as well as branded business across the globe.
Ranbaxy transfers R&D unit to Daiichi Sankyo
Ranbaxy Laboratories has transferred its research division for new drugs to Japan’s Daiichi Sankyo turning Ranbaxy into a pure generic drugmaker.
Load More
